Is Bio-Techne Corporation (TECH)’s Fuel Running Low? The Stock Reaches Record High Today

April 17, 2018 - By Marguerite Chambers

Bio-Techne Corporation (NASDAQ:TECH) Logo

Investors sentiment decreased to 0.98 in 2017 Q4. Its down 0.23, from 1.21 in 2017Q3. It worsened, as 27 investors sold Bio-Techne Corporation shares while 88 reduced holdings. 34 funds opened positions while 79 raised stakes. 35.53 million shares or 1.06% less from 35.91 million shares in 2017Q3 were reported.
Us Fincl Bank De reported 59,136 shares or 0.02% of all its holdings. Advantus Capital Mgmt has invested 0.01% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,069 shares stake. Ftb Advsr Inc has invested 0% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Guggenheim Cap Llc holds 0.02% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH) for 78,261 shares. Profund Advsrs Limited Liability invested in 17,816 shares or 0.09% of the stock. Retail Bank Of America De holds 0.01% or 262,312 shares. Moreover, Conestoga Cap Advsrs Llc has 1.37% invested in Bio-Techne Corporation (NASDAQ:TECH) for 274,822 shares. Moreover, Jpmorgan Chase & has 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 43,094 shares. Eaton Vance Management reported 2,535 shares. Brown Advisory invested in 5,665 shares. Castleark Management Limited Liability Company holds 43,315 shares or 0.17% of its portfolio. Friess Ltd has 1.55% invested in Bio-Techne Corporation (NASDAQ:TECH). Veritable Limited Partnership accumulated 4,932 shares or 0.01% of the stock. Magnetar Fincl Limited Co has invested 0.01% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH).

Since February 13, 2018, it had 0 insider purchases, and 1 insider sale for $680,303 activity.

The stock of Bio-Techne Corporation (NASDAQ:TECH) reached all time high today, Apr, 17 and still has $159.36 target or 5.00 % above today’s $151.78 share price. This indicates more upside for the $5.69 billion company. This technical setup was reported by Barchart.com. If the $159.36 PT is reached, the company will be worth $284.40 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 1.23% or $1.845 during the last trading session, reaching $151.775. About 74,566 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 45.31% since April 17, 2017 and is uptrending. It has outperformed by 33.76% the S&P500.

Analysts await Bio-Techne Corporation (NASDAQ:TECH) to report earnings on May, 1. They expect $1.08 EPS, up 21.35 % or $0.19 from last year’s $0.89 per share. TECH’s profit will be $40.47 million for 35.13 P/E if the $1.08 EPS becomes a reality. After $0.91 actual EPS reported by Bio-Techne Corporation for the previous quarter, Wall Street now forecasts 18.68 % EPS growth.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 6 analysts covering Bio-Techne Corporation (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Bio-Techne Corporation had 9 analyst reports since October 24, 2017 according to SRatingsIntel. Deutsche Bank maintained the shares of TECH in report on Thursday, March 1 with “Buy” rating. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Craig Hallum on Wednesday, February 7. The firm has “Buy” rating given on Thursday, January 18 by Robert W. Baird. Stephens maintained it with “Hold” rating and $142.0 target in Wednesday, February 7 report. Robert W. Baird maintained the stock with “Buy” rating in Tuesday, October 31 report. Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) rating on Tuesday, February 6. Robert W. Baird has “Buy” rating and $157.0 target. The rating was maintained by Robert W. Baird on Monday, October 23 with “Buy”. The company was maintained on Tuesday, December 5 by Leerink Swann.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.69 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 49.91 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.